Apex Biotechnology Corp. · TWSE:1733
Apex Biotechnology — Investor Conference (June 2025)
16 slides from Apex Biotechnology's conference presentation, Jun 5, 2025
Slide 1: May 2025
May 2025
Slide 2: Company profile
Company profile 2 TSEC 1733 Industry IVD Medical Device Operation Locations .Head quarter: No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan .Tao Yuan Factory: No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Taoyuan City, Taiwan .Suzhou Corp.: Room 106, No.2, Kecheng Road, SIP, Suzhou, China
Slide 3: Milestone
Milestone 3 1997-2001 2002-2006 2007-2011 1997 ApexBio set-up 2002 ISO 9001/13485 notified 2007 Lactate launch 1998 BGM FDA 510K approval 2003 CE IVDD notified 2008 oice BGM launch 1999 Uric Acid patent granted 2005 Pesticide residues check 2009 Taoyuan factory set-up 2000 IPO listed to Taiwan OTC p
Slide 4: Quality System
Quality System 4 Region The Authority Regulatory compliance Taiwan TFDA QMS ISO 13485:2016 EU CE CE mark number:CE0197 EN ISO 15197:2015 Quality System Regulation (21 CFR Part 820) USA FDA 510K’s on-site audit w/o 483 citations 2023 MDSAP (USA/Canada/Brazil) China NMPA Medical Device Class II 2017 p
Slide 5: Product profile
Product profile Blood glucose monitoring systems Professional Monitoring systems ◼ Uric Acid ◼ Hemoglobin ◼ Lactate ◼ Ketone 5
Slide 6: Multi-functional systems Eclipse PLUS
Multi-functional systems ◼ Glucose + Ketone ◼ Glucose + Cholesterol + TG + Uric Acid Eclipse PLUS For Clinic and Hospital Pre-screening Diabetic Kidney Disease • HbA1c • Microalbumin • Creatinine • ACR 6
Slide 7: GLUCOSURE POC
Ketone POC barcode scanner + Wi-Fi Hospital GLUCOSURE POC Glucose/Ketone POC barcode scanner + Wi-Fi 7
Slide 8: Hemoglobin and Blood Lactate Monitoring Systems
Hemoglobin Monitoring System Blood Lactate Monitoring System 7
Slide 9: 8-in-1 Point of Care Monitoring System
8-in-1 Point of Care Monitoring System ◼Blood Glucose ◼Uric Acid ◼Cholesterol & LDL ◼Hemoglobin ◼Lactate ◼Ketone ◼Creatinine ◼Triglycerides 7
Slide 10: New pipeline products
New pipeline products 10 ◼ Rapid test TFDA QMS passed • COVID-19 Antigen Rapid Test Kit • KP Rapid Test Kit • Influenza Rapid Test Kit Developing items: • Vector-borne Disease Detection for Mosquito-borne Illnesses • Economic Animal and Animal Epidemic Prevention Detection • DOA ◼ Home use CGM
Slide 11: Customized projects
Customized projects 11 ◼ Product platform focus on electrochemistry/photometry/ Lateral flow assay, to derive new parameter tests and optimize our core platform. ◼ Sharing our advantage of regulation/quality control/sales channels/clinical trails/manufacturing to alliance with partners and customers
Slide 12: Global sales distribution
Global sales distribution 12 Territory 2023 2024 2025/1Q America 41% 39% 52% EU 44% 48% 41% Asia 13.5% 12% 6% Africa 1.5% 1% 1%
Slide 13: Finance Performance
Finance Performance 13 Year 2023 2024 2025/1Q Revenue 1,676,537 1,852,211 558,753 Gross margin 531,116 521,342 162,659 Operation profit 141,716 128,464 56,200 Profit after tax 115,714 128,104 61,988 EPS 1.16 1.28 0.62 G/M ratio 31% 28% 29% Shipped Meter Qty (kit) 1,189K 1,368K 331K Shipped Strip Qty
Slide 14: Product ratio
Product ratio 14 2024 2025/1Q BGM & A1C Electrode BGM & A1C Electrode Non-BGM Others Non-BGM Others 5% 3% 10% 2% 15% 6% 74% 85% Non-BGM Hemoglobin/Ketone/Uric Acid/Lactate/Cholesterol/ Pesticide quick check etc.
Slide 15: The 11th Corporate Governance Evaluation (2024)
the 11th Corporate Governance Evaluation (2024) 15 Points for Number of AA/A+ Total number of Distribution Category satisfied inapplicable Extra Credit indicators weight indicators indicators Indicators Year 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 Protecting Shareholder Rights and Interest
Slide 16: Thank you
Thank you Taiwan